All News

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

During Kidney Cancer Awareness Month, Dr. Eric Singer shares warning signs, risk factors and when younger adults should speak with a doctor about kidney health.

Dr. Jonathan W. Friedberg says long-term data show 42% of treated follicular lymphoma patients achieved functional cure with chemoimmunotherapy.

Dr. Kevin Kalinsky discusses common side effects associated with the FDA-approved combination of Enhertu and Perjeta for breast cancer.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

Phase 2 interim data show NDV-01 produced high response rates and encouraging safety in patients with non–muscle-invasive bladder cancer.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

Fifteen-year follow-up from the S0016 trial found over one-third of patients with follicular lymphoma treated with chemoimmunotherapy had no progression.

Dr. Christopher Koller discusses rising kidney cancer diagnoses in younger adults, key risk factors and why early detection remains critical.

A personal look at choosing to be a caregiver, the challenges faced, and the lessons learned while supporting a sister through years with cancer.

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for patients with TNBC.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.

FDA grants priority review to Enhertu for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Clinical trial data show a carboplatin-free regimen offers similar results with fewer side effects for patients with stage 2 to 3 HER2+ disease.

Zovegalisib plus Faslodex elicited responses in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer.

Manage your stage 3 ET diagnosis with this guide on high-risk treatments, side effects and new NCCN-preferred options to empower your next visit.

Here are five key takeaways regarding the use of GLP-1 receptor agonists in patients who are undergoing breast cancer treatment.

At the Miami Breast Cancer Conference, Dr. Heather A. Parsons shared growing evidence for the prognostic value of circulating tumor DNA.

A comprehensive guide to medullary thyroid cancer (MTC), covering symptoms, RET genetic testing, surgical options and advanced targeted therapies.

New data show that Enhertu had similar safety in the real world as in clinical trials in patients with HER2-low metastatic breast cancer.

A community study finds Enhertu effective for HER2-low mBC, with over half of patients seeing tumor shrinkage and high one-year survival rates.

New data show more women over 70 are safely skipping sentinel lymph node biopsies for HR+ breast cancer, reducing unnecessary surgery and risks.

After abnormal mammogram, family history and testing revealed a BRCA1 mutation, leading one woman to choose preventive surgeries and share her experience.

Resilience programs using mindfulness and cognitive behavioral strategies help cancer survivors manage their fear and stress, as well as adjust after treatment.